Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,412 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active capsule Clear all
Active, not recruiting Phase 3 Interventional

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

NCT05409066
View directory record Official record
Conditions
Follicular Lymphoma (FL)
Interventions
Epcoritamab, Rituximab, Lenalidomide
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
31
States / cities
Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants

NCT04914377
View directory record Official record
Conditions
Covid19
Interventions
TQ Formula/Tab
Drug
Lead sponsor
Novatek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
San Diego, California • Hialeah, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 21, 2026, 2:41 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

LDX for the Treatment of Cognitive Functioning Issues in Women Post-Oophorectomy

NCT01986777
View directory record Official record
Conditions
Cognitive Impairments, RRSO
Interventions
lisdexamfetamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 60 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 21, 2026, 2:41 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Gene by Medication Interaction to the Acute Effects of Alcohol

NCT01343628
View directory record Official record
Conditions
Alcohol-induced Cue-craving, Alcohol Sensitivity
Interventions
Placebo Comparator, Active Comparator: Atomoxetine, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Charlottesville/ Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Phase 1 Interventional

Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis

NCT01759056
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
AVX 470, Placebo
Drug
Lead sponsor
Avaxia Biologics, Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
Anaheim, California • Lakewood, Colorado • Winter Park, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Phase 3 Interventional

An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder

NCT00629551
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
saredutant (SR48968), paroxetine, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Phase 1 Interventional

Omega-3 and Therapy Study for Childhood Bipolar Disorder- Not Otherwise Specified

NCT01507753
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Omega-3 Supplementation, Psychoeducational Psychotherapy (PEP), Placebo
Drug · Behavioral · Other
Lead sponsor
L. Eugene Arnold
Other
Eligibility
7 Years to 14 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Oct 21, 2026, 2:41 AM EDT
Terminated Phase 3 Interventional Results available

Tiotropium/Salmeterol Inhalation Powder in COPD

NCT00668772
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium/Salmeterol, Salmeterol, Placebo, Tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
16
States / cities
Anniston, Alabama • Mobile, Alabama • Clearwater, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Phase 1 Interventional

Oral AMXT 1501 Dicaprate in Combination With DFMO

NCT03536728
View directory record Official record
Conditions
Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
Interventions
AMXT1501, DFMO
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Austin, Texas • Houston, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Phase 3 Interventional Results available

The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)

NCT01106677
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin, Sitagliptin, Metformin immediate release
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
45
States / cities
Little Rock, Arkansas • Fountain Valley, California • National City, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 21, 2026, 2:41 AM EDT
Active, not recruiting Phase 2 Interventional

Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia

NCT07033481
View directory record Official record
Conditions
Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
Interventions
Neflamapimod, Placebo
Drug
Lead sponsor
EIP Pharma Inc
Industry
Eligibility
40 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Chicago, Illinois • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 21, 2026, 2:41 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effectiveness of a Novel Dietary Ingredient on Hair Growth and Skin's Appearance

NCT06010745
View directory record Official record
Conditions
Hair Thinning, Facial Skin Texture, Skin Ageing
Interventions
Biotin and silicon, Placebo
Dietary Supplement
Lead sponsor
Nutrition 21, Inc.
Industry
Eligibility
35 Years to 70 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Whole Coffee Fruit Concentrate Pilot Study 1

NCT01965795
View directory record Official record
Conditions
Brain-derived Neurotrophic Factor (BDNF), Cognitive Function, Affect
Interventions
Whole Coffee Fruit Concentrate (WCFC), Nutrim
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Not applicable Interventional Results available

Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder

NCT05903495
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Deep Brain Stimulation
Device
Lead sponsor
West Virginia University
Other
Eligibility
22 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia

NCT02538965
View directory record Official record
Conditions
Leukemia, Myeloid
Interventions
Lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
1 Year to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Pain Associated With Fibromyalgia

NCT02187471
View directory record Official record
Conditions
Pain Associated With Fibromyalgia
Interventions
DS-5565, Pregabalin, Placebo tablet, Placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
91
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Oct 21, 2026, 2:41 AM EDT
Terminated Not applicable Interventional

Pilot Study of Dietary Modification of Appetite Set Point in Obesity

NCT00726271
View directory record Official record
Conditions
Obesity
Interventions
light olive oil, fish oil capsules, flax seed oil capsules
Dietary Supplement
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Oct 21, 2026, 2:41 AM EDT
Not listed Phase 3 Interventional

Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia

NCT01229566
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
AKR-963
Drug
Lead sponsor
Trygg Pharma, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 24, 2011 · Synced Oct 21, 2026, 2:41 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

NCT04806451
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Crinecerfont, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

Nicotinic Receptors and Schizophrenia

NCT01400477
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
DMXB-A-SR, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

A New Oral Treatment For Type II Diabetes Mellitus

NCT00111800
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, DEN 2.5 mg, DEN 7.5 mg, DEN 15 mg, DEN 30 mg, DEN 45 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
36
States / cities
Long Beach, California • Pasadena, California • Denver, Colorado + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 21, 2026, 2:41 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis

NCT05044234
View directory record Official record
Conditions
Psoriasis
Interventions
Cedirogant, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 21, 2026, 2:41 AM EDT
Not listed Phase 1 Interventional

A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's

NCT06309147
View directory record Official record
Conditions
Parkinson Disease
Interventions
BMS-9894923
Drug
Lead sponsor
Allyx Therapeutics
Industry
Eligibility
50 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 21, 2026, 2:41 AM EDT
Completed No phase listed Observational

Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants With Bipolar I Disorder

NCT06256367
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Birmingham, Alabama • Beverly Hills, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 21, 2026, 2:41 AM EDT